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Forty-one patients suffering from grass pollen allergy underwent specific immunotherapy with
standardized allergen extract consisting of six grass pollens (H-Al per os) administered either
sublingually or supralingually for one year. In order to investigate clinical and immunological
changes induced by the administration of allergens via the oral mucosa, the double-blind, pla-
cebo-controlled, randomized design of the trial with 30 other patients enrolled in placebo
groups was applied.
Specific immunotherapy with oral drops administered sublingually or supralingually was per-
formed in the sameway, keeping the drops under or on the tongue, respectively, for 1e2 min before
swallowing them; at the end of the trial the cumulative dose of the allergen was almost 20 times
higher than that of the subcutaneous therapy with corresponding allergen preparation. Data about
symptoms scores and drugs intake during grass pollen season, as well as skin reactivity, levels of
specific IgG and IgE antibodies, before the study and after the study’s completion, were obtained.
It was found that both routes of administration are effective according to subjective clinical
parameters and drug consumption, with a highly significant reduction of symptoms and drug intake
favoring sublingual administration where a reduction of more than 60% was achieved. Only sublin-
gual active group showed a significant increase in Dactylis glomerata-specific IgG serum levels.
Adverse effects were limited to a small number of generally mild local and/or systemic reactions.
The results suggest that the administration of allergens via the oral mucosa is safe and clinically
effective, favoring the sublingual rather than supralingual route.
ª 2008 Elsevier Ltd. All rights reserved.377 104 343; fax: þ420 377 103 397.
cz (P. Panzner).
8 Elsevier Ltd. All rights reserved.
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Over the last 20 years, interest in non-injection routes for
allergen-specific immunotherapy has increased, especially
in Europe.13,14 These routes (oral, nasal, bronchial) have
the overall aim of improving both safety and compliance.1
During the past years particularly the oral route has
become a promising way for administration of SIT, sublin-
gual route being the most evidenced one. In spite of this,
various manufacturers of vaccines still recommend slightly
different ways of oral administration.
Administration of specific immunotherapy with allergen
extract ‘‘H-Al per os’’ produced by Sevapharma a.s.,
Prague, Czech Republic, is recommended either sublin-
gually or supralingually in the same way, keeping the drops
under or on the tongue, respectively, before swallowing
them.
This randomized double-blind controlled trial was aimed
at assessing the clinical efficacy and safety of specific
immunotherapy to grass pollen in adults and children with
sublingual or supralingual administration. The primary
efficacy criteria were symptom score and rescue medica-
tion consumption during the grass pollen season. Dactylis
glomerata pollen specific IgG and IgE serum levels and
skin reactions were considered to be secondary parame-
ters.4,5,9e11
Grass pollen extract (H-Al per os) was chosen because
grass pollen is the most important allergen in the Czech
Republic and it represents the causative agent in about 70e
90% of allergic patients.16Material and methods
Patients
Seventy four patients were enrolled in the trial. Three
patients were withdrawn during treatment (before the
grass pollen season) for inadequate cooperation. The
clinical trial was finished by 71 patients (41 male, 30
female, aged 7e50 years; mean 19.5 years).Table 1 Characteristics of subjects eligible for analysis
Active tr
Sublingu
No. of subjects 20
Male/female 11/9
Age distribution (years) 17.4 9
Seasonal rhinitis in at least two previous
grass seasons
20
Seasonal conjunctivitis in at least two
previous grass seasons
15
Asthma during previous pollen seasons 0
Sensitizations other than grass and major
inhalant coinciding allergens
10
Previous SIT interrupted for more than five years 0
Dactylis glomerata specific IgE
before treatment >3.5 kU/l
20All patients had seasonal rhinitis and/or conjunctivitis
(without asthma) caused by grass pollen, had experienced
symptoms in at least the previous two years and none of the
patients had previous treatment with SITwithin the last five
years.
The diagnosis of allergy to grass pollen was made by
clinical history, positive skin tests to standardized pollen
extract e Grass mixture I and Dactylis glomerata (Seva-
pharma a.s., Prague, Czech Republic) e and the presence
of specific IgE to the mixture of grass pollens shown by the
CAP System (Pharmacia Diagnostics AB, Uppsala, Sweden)
with class 3 as a minimum value (at minimum 3.5 kU/l).
The exclusion criteria included sensitization (evidenced
by skin prick tests) to major inhalant allergens coinciding
with the grass pollen season e ash (Fraxinus excelsior),
lime (Tilia cordata), elderberry (Sambucus nigra), dande-
lion (Taraxacum officinale), plantain (Plantago lanceolata)
and nettle (Urtica dioica), systemic immunologic or meta-
bolic disease, malignancies, major anatomic alterations of
the upper airways, severe atopic dermatitis, chronic
corticosteroid or beta-blocker treatment, pregnancy,
chronic or recurrent inflammation of oral mucosa and other
contraindications of SIT.
All the patients, or parents of the minors, were informed
in detail about the experimental procedure and provided
written informed consent.
Allergen preparations
The standardized allergen extract ‘‘H-Al per os’’ (Seva-
pharma a.s., Prague, Czech Republic) used throughout
the study was a mixture of six species of grass pollens
(Grass mixture I): oat grass (Arrhenatherum elatius),
orchard grass (Dactylis glomerata), fescue (Festuca sp.),
rye grass (Lolium sp.), timothy grass (Phleum pratense)
and rye (Secale cereale). The concentrations of the
solutions were as follows: 1, 10, 100, 1000 and 10 000
JSK/ml, respectively.
Active principle is expressed in biologic units (JSK e
jednotka standardnı´ kvality e standard quality unit). The
biologic activity is defined as follows: a prick test with aneatment Placebo treatment
al Supralingual Sublingual Supralingual
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Figure 1 Daily cumulative score means of nasal, ocular and
bronchial symptoms including daily drug intake mean in
dependence of grass pollen season development (2004) in all
treated groups.
1298 P. Panzner et al.extract containing 1000 JSK/ml produces a wheal with
a mean diameter of 5.5 mm in a minimum of 20 patients
sensitized to the allergen under consideration (definition
of allergen producer). The maximal dose (10 drops of
10 000 JSK/ml) contains approximately 1.265 mg of the grass
pollen major allergen Lol p I according to the producer.
Placebo preparations were identical to the active
therapy in composition, appearance, presentation, taste,
and color, but obviously contained no allergen.
Treatment
A scheme of increasing doses was used, with drops to be
taken by the sublingual or supralingual route once daily,
increasing from 1 to 10 drops for each vial until the maximal
dose (10 drops of 10 000 JSK/ml) was reached.
The treatment was started in autumn and was followed
by a maintenance therapy with 10 drops of 10 000 JSK/ml
three times a week for one year.
The patients using sublingual therapy were instructed to
keep the drops under the tongue for 1e2 min before swallow-
ing them, while the patients using specific immunotherapy
administered supralingually had to keep the drops on the
tongue for 1e2 min before swallowing them.
Before the start of the grass pollen season (May 2004),
the cumulative dose of allergen extract, received by each
patient, was more than 350 000 JSK independently of the
route of administration or on the preparation (allergen or
placebo). The differences of the cumulative dose in all
groups were not significant (PZ 0.69).
According to the schedule, by the end of the trial
(September 2004), an average total cumulative dose was
more than 580 000 JSK. The difference among therapeutic
groups was not significant (PZ 0.28).
All patients were allowed to use, when necessary, the
following drugs as rescue medication: levocabastine,
cromoglycate, azelastine, budesonide, beclomethasone
(local antiallergic medication), cetirizine or loratadine
(oral antihistamines), prednisone and salbutamol (oral
corticosteroid and inhaled beta 2-agonist).
Design of the study
This one-year clinical study was conducted according to the
rules of Good Clinical Practice (GCP) and was approved by
the Ethics Committee of the Czech Ministry of Health and
State Institute for Drug Control. A multicenter, double-
blind, randomized, placebo-controlled parallel design for
both routes of administration (sublingually or supralin-
gually) was used with no dummy arrangement. The trial
was carried out in nine study centres.
Screening procedures prior to study inclusion/exclusion
were conducted from May to August 2003. One-year specific
allergen immunotherapy was performed from September
2003 to October 2004.2,10
Patients enrolled in the trial were randomized to receive
either the active sublingual/supralingual therapy or pla-
cebo sublingual/supralingual therapy (see Table 1). Each
suitable patient was assigned to the treated group due to
the central randomization. The randomization key was
generated by the GraphPad Software, Inc. 10855 Sorrento
Valley Road 203 San Diego, CA 92121, USA.Throughout the treatment, the patients had to record the
following data in a diary: study treatment administration,
rescue medication, adverse events and concomitant
treatment. The patients also completed a daily record of
Table 2 Summary of cumulative scores of symptoms (nasal, ocular and bronchial) and mean frequency of rescue medication
consumption in all treated groups for grass pollen season
Oral drops administered
sublingually
Oral drops administered
supralingually
Active
(20 subjects)
Placebo
(15 subjects)
Active
(21 subjects)
Placebo
(15 subjects)
Total symptoms score
Mean cumulative score of
symptoms standard error (95%CI)
203.5 49.34
(100.24e306.76)
611.07 124.16
(344.74e877.39)
388.81 67.59
(247.81e529.80)
624.33 104.59
(399.99e848.67)
Improvement (%) e related to placebo group 66.7 37.7
P (ManneWhitney U test) 0.0029a 0.7130b 0.0891a 0.0285c
Power (%) 90a 3b 48a 57c
Nasal symptoms
Mean cumulative score of
symptoms standard error (95%CI)
111.35 25.69
(57.57e165.13)
321.6 54.54
(204.62e438.58)
204.71 30.85
(140.37e269.06)
345.8 49.31
(240.03e451.57)
Improvement (%) e related to placebo group 65.4 40.8
P (ManneWhitney U test) 0.0017a 0.7437b 0.0356a 0.0258c
Power (%) 95a 5b 70a 62c
Ocular symptoms
Mean cumulative score of
symptoms standard error (95%CI)
60.20 18.17
(22.18e98.22)
185.67 47.47
(83.84e287.49)
113.48 23.01
(65.47e161.49)
194.00 37.74
(113.05e274.95)
Improvement (%) e related to placebo group 67.6 41.5
P (ManneWhitney U test) 0.0130a 0.4937b 0.0832a 0.0951c
Power (%) 75a 3.5b 47a 42c
Bronchial symptoms
Mean cumulative score of
symptoms standard error (95%CI)
31.95 10.66
(9.64e54.26)
103.80 39.16
(19.80e187.80)
70.62 21.75
(25.24e116.00)
84.53 26.34
(28.04e141.02)
Improvement (%) e related to placebo group 69.2 16.5
P (ManneWhitney U test) 0.0299a 0.7400b 0.4800a 0.2184c
Power (%) 50a 6b 5a 33c
Rescue medication intake
Mean frequency of drug
intake standard error (95%CI)
4.60 1.36
(1.75e7.45)
13.93 4.60
(4.06e23.81)
10.33 3.40
(3.24e17.42)
16.80 4.74
(6.64e26.96)
Reduce (%) e related to placebo group 67.0 38.5
P (ManneWhitney U test) 0.0360a 0.6676b 0.2620a 0.1323c
Power (%) 56a 3b 20a 32c
a ActiveePlacebo at the same administration route.
b PlaceboePlacebo.
c ActiveeActive.
Evaluation of grass pollen specific immunotherapy 1299the presence and severity of symptoms during the grass
pollen season (May 2004eSeptember 2004).
Before treatment initiation (SeptembereOctober 2003)
and at study completion (after one year of treatment),
quantitative prick tests to Grass mixture I and to Dactylis
glomerata were performed, and blood samples were
collected and stored frozen for antibody assays at study
completion.4,5,9e11
The primary endpoint of this study was defined by
symptoms scores. In addition, the rescue medication intake
score, skin prick tests and grass pollen specific antibodies IgE
and IgG were considered as secondary outcomes of this trial.
Symptoms scores
Throughout the grass pollen season, rhinitis, conjunctivitis
andbronchial symptomswere recordeddaily by thepatients.Records were based on four symptoms: rhinitis symptoms e
sneezing, nasal itching, watery runny nose, nasal obstruc-
tion; conjunctivitis symptoms e ocular redness, ocular
itching, tearing and ocular swelling; bronchial symptoms e
cough, presence of mucus, breathlessness, wheezing.
Each symptom was rated on the following four-point
scale: 0: no symptom; 1: mild complaints (signs or symp-
toms present but not disturbing); 2: moderate complaints
(signs or symptoms disturbing); 3: severe complaints (very
disturbing signs with impaired social or professional life,
usual necessity of rescue medication).
A very rigorous condition how to assess the symptom
score while using permitted rescue medication was set in
this trial. Patients who used the rescue medication had to
have assigned 3 points to at least one symptom. On the
other hand, the patients could record a 3 point score
without using the symptomatic medication.
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Figure 2 Cumulative scores of symptoms and mean number
of drug intake days for grass pollen season in all treated
groups.
1300 P. Panzner et al.Medication scores
Throughout the study, the patients were instructed to use
symptomatic medications (rescue medication) if needed
and to record the amounts used. The daily use of any
permitted rescue medication was assessed by score 1. If
subjects did not take any concomitant drug, the daily score
was 0.
Skin prick tests
Quantitative prick tests were performed at inclusion
and at treatment completion with Grass mixture I
allergen extract at a concentration of 1000 JSK/ml and
with Dactylis glomerata allergen extract at a concentra-
tion of 10, 100, 1000 and 10 000 JSK/ml. Prick tests
were also performed with positive control and negative
control.
The wheals were outlined with a fine-tip roller ball pen
and transferred by means of transparent tape to the
corresponding sheet of the Case Report Form (CRF). Wheal
diameters were calculated from surfaces digitized by
scanning.5,8
The least-squares method was used to calculate the
following regression line equation: yZ aþ b*log(c), where
yZ diameter of the wheal, aZ intercept, bZ slope,
cZ concentration. This regression line, which was the
doseeresponse curve (concentration by wheal diameter),
was used to calculate the theoretic wheal diameter
obtained in response to a concentration of 1000 JSK/ml in
each patient before and after treatment.
Specific IgE and IgG
Blood was taken at the inclusion of the patients and at the
end of the study. Sera were frozen, collected and stored in
the central site. The store temperature was less then
30 C. Analyses were carried out by the central labora-
tory. Dactylis glomerata-specific IgE and IgG levels were
determined by the CAP System (Pharmacia Diagnostics,
Uppsala, Sweden) and the IgG ELISA Fooke test (Dr. FOOKE
Laboratorien GmbH, Neus, Germany), respectively.
Pollen counts
The pollen season of the grasses in the Czech Republic
starts at the beginning of May and lasts until the beginning
of August (from the 21st week to the 32nd week). Pollen
grain counts were recorded by the Czech Pollen Information
Service (PIS).
Statistical methods
The investigated parameters might be non-normally
distributed, and therefore the ManneWhitney U test for
intergroup comparison and the Wilcoxon test for intragroup
comparisons were used when appropriate. All tests were
two-tailed, and the level of significance was set at 0.05.
All the statistical analyses have been performed with the
biostatistics software StatMate (GraphPad, version 1.01i,
16/1/1998).
Evaluation of grass pollen specific immunotherapy 1301Results
Symptom scores and rescue medication
The daily cumulative score of nasal, ocular and bronchial
symptoms including the daily frequency of symptomatic
medication intake in the real grass pollen season (from the
21st week to the 32st week) are plotted in Fig. 1. The daily
cumulative scores and daily drug intake mean in four
treated groups (sublingual and supralingual active groups
plus both placebo groups) coincide with the grass pollen
peaks. Marked differences were evident in observed clinical
symptoms and drug intake favoring both active treatments.
These differences between both actives and both placebo
groups are decreased with the grass grain count falling
(roughly from the 32nd week).
The results, reported in Table 2 and Fig. 2, confirm the
reduction of total symptoms occurrence and intensity of
38% and 67% in patients of the supralingual and sublingual
active groups, respectively, related to patients of both
placebo groups. The comparison between both active
treated groups showed greater symptom reduction in the
sublingual active group compared to the supralingual active
group, with a significant difference (PZ 0.0258) only in the
clinical manifestation of nasal symptoms.Table 3 Summary of Dactylis glomerata and grass mixture I ski
Oral drop
sublingua
Active
Dactylis glomerata SPT (mm)
Mean wheal diameter standard error (95%CI)
Before treatment 5.1 0.38
(4.3e5.89
After one-year treatment 4.29 0.5
(3.24e5.3
Change wheal diameter (mm) e related to
diameter before treatment
0.8 0.
(1.7e0.
Wheal diameter decrease: number of patients (%) 13 (65%)
Wheal diameter increase: number of patients (%) 7 (35%)
P (Wilcoxon matched-pairs test) e
intragroup beforeeafter
0.1054
P (ManneWhitney Test) e intergroup change
wheal diameter
0.9867
Grass mixture I SPT (mm)
Mean wheal diameter standard error (95%CI)
Before treatment 7.33 0.5
(6.24e8.4
After one-year treatment 6.37 0.9
(4.39e8.3
Change wheal diameter (%) e related to
diameter before treatment
0.96 0
(2.69e0
Wheal diameter decrease: number of patients (%) 14 (70%)
Wheal diameter increase: number of patients (%) 6 (30%)
P (Wilcoxon matched-pairs test) e
intragroup beforeeafter
0.1769
P (ManneWhitney Test) e intergroup change
wheal diameter
0.9336The consumption of medication (the necessity of using
rescue medication) was lower by 67% (PZ 0.036) in sublin-
gually treated patients compared to the placebo group, the
same consumption reached a reduction of only 38.5% in
supralingually treated patients compared to the placebo
group. The difference in this case was not significant
(PZ 0.1323).
Skin prick tests
The mean wheal diameter size in response to Dactylis
glomerata or Grass mixture I at a concentration of
1000 JSK/ml, predicted by the doseeresponse curve, was
not significantly different among any of the active or pla-
cebo groups at baseline or after treatment completion.
The summary of results is reported in Table 3.
Nevertheless, a decrease in wheal diameter was seen
not only in both active treatment groups but also in the
placebo groups. In the sublingual active group, there was
no significant difference in variations from baseline to
treatment completion for both allergens (Dactylis glomer-
ata and Grass mixture I) but in the supralingual active
group, there was a significant difference in mean wheal
to Dactylis glomerata (PZ 0.01) before and after treat-
ment completion.n prick test (SPT) results in all treated groups
s administered
lly
Oral drops administered
supralingually
Placebo Active Placebo
)
5.34 0.45
(4.38e6.3)
5.4 0.33
(4.71e6.09)
4.91 0.35
(4.17e5.66)
5)
4.28 0.51
(3.2e5.37)
4.09 0.36
(3.33e4.85)
4.48 0.56
(3.27e5.69)
43
1)
1.06 0.63
(2.41e0.3)
1.31 0.42
(2.19e0.43)
0.44 0.59
(1.71e0.83)
10 (67%) 17 (81%) 10 (67%)
5 (33%) 4 (19%) 5 (33%)
0.0946 0.0101 0.5245
0.3521
2
2)
7.68 0.69
(6.19e9.16)
7.8 0.75
(6.25e9.36)
8.12 0.92
(6.14e10.1)
5
6)
6.5 0.87
(4.63e8.36)
6.36 0.75
(4.79e7.93)
7.09 1.08
(4.78e9.4)
.83
.77)
1.18 0.59
(2.45e0.1)
1.45 0.71
(2.93e0.04)
1.03 1.08
(3.35e1.29)
11 (73%) 15 (71%) 11 (73%)
4 (27%) 6 (29%) 4 (27%)
0.0554 0.0595 0.2078
>0.9999
1302 P. Panzner et al.There was no correlation between skin prick tests and
symptoms and/or drug intake scoreswithin both active groups
of patients and placebo groups similarly as elsewhere.4,5,10
IgE and IgG antibodies
Increase of IgE after one year of treatment was not
significant in any treated group. No significant variation of
specific Dactylis glomerata IgE was detected between the
active and placebo groups before or after treatment
completion.
Table 4 shows a significant increase (PZ 0.02) in Dacty-
lis glomerata specific IgG serum levels in the sublingual ac-
tive group related to the corresponding placebo group after
one year of treatment. The IgG level increase was achieved
in 85% of the patients of the sublingual active group.
Safety
During the trial, no serious allergen immunotherapy-related
adverse effect was observed.
Local adverse effects were documented in three
patients of the sublingual active group (11 events) and in
five patients of the supralingual active group (22 events),Table 4 Summary of Dactylis glomerata specific IgG and IgE re
Oral drops administer
sublingually
Active P
Dactylis glomerata specific IgG (mg/ml)
GMT standard error (95%CI)
Before treatment 27.13 17.46
(15.38e88.47)
4
(
After one-year treatment 47.82 13.68
(38.64e95.88)
5
(
Mean change of IgG (%) e related
to IgG before treatment
138.8 46.85
(40.74e236.85)
6
(
IgG decrease: number of patients (%) 3 (15%) 6
IgG increase: number of patients (%) 17 (85%) 9
P (Wilcoxon matched-pairs test) e
intragroup beforeeafter
0.0240 0
P (ManneWhitney Test) e
intergroup change IgG
0.0620
Dactylis glomerata specific IgE (U/ml)
GMT standard error (95%CI)
Before treatment 57.04 19.8
(59.29e142.18)
2
(
After one-year treatment 57.69 17.63
(62.44e136.24)
3
(
Mean change of IgE (%) e related to
IgE before treatment
39.15 19.58
(1.83e80.13)
5
(
IgE decrease: number of patients (%) 6 (30%) 3
IgE increase: number of patients (%) 14 (70%) 1
P (Wilcoxon matched-pairs test) e
intragroup beforeeafter
0.3683 0
P (ManneWhitney Test) e
intergroup change IgE
0.1994whereas only together in three patients from both placebo
groups 5 events were found. The local adverse effects
consisted of undesirable taste, difficulty in swallowing,
tongue or lips swelling, burning of the lips or mouth, itching
of the tongue, throat or mouth.
Systemic adverse effects were observed only in patients
of both active groups except for one case reported in one
patient of the placebo group. Nine patients from the
supralingual and six patients from the sublingual active
group reported 33 events and 34 events of systemic adverse
effects, respectively. These were represented by rhinitis,
painful or difficult breathing, breathlessness, cough,
conjunctivitis, sneezing, ear itching, abdominal pain, head-
ache, heartburn, nausea and fatigue.
The number of patients with at least one local adverse
effect was not significantly different between the both
active and placebo groups (Fisher’s exact test). On the
other hand, the number of patients with at least one
systemic adverse effect was significantly higher in both
active groups than in the placebo groups (PZ 0.027 and
PZ 0.0245 for the group with sublingual and supralingual
SIT, respectively). Occurrence of these systemic effects
was in both active group with no significant difference.
The documented local and systemic adverse effects
correspond to the side reactions reported in the leafletsults in all treated groups
ed Oral drops administered
supralingually
lacebo Active Placebo
3.62 16.77
43.26e115.22)
56.97 22.79
(44.06e139.16)
53.96 12.01
(44.05e95.59)
1.72 25.39
38.5e147.43)
67.67 21.49
(55.25e144.93)
46.64 8.77
(37.93e75.56)
3.09 40.84
24.52e150.7)
74.12 40.8
(11e159.24)
7.88 22.73
(40.89e56.65)
(40%) 9 (43%) 9 (60%)
(60%) 12 (57%) 6 (40%)
.5614 0.3038 0.2078
0.1581
6.71 13.65
23.77e82.33)
47.21 14.79
(46.55e108.24)
36.63 13.27
(31.98e88.9)
9.06 17.94
43.83e120.79)
53.48 20.81
(48e134.82)
38.14 14.32
(31,44e92.89)
55.41 425.05
356.31e1467.14)
40.31 18.2
(2.35e78.28)
27.19 23.08
(22.33e76.7)
(20%) 8 (38%) 8 (53%)
2 (80%) 13 (62%) 7 (47%)
.0637 0.1373 0.8469
0.4042
Table 5 Summary of adverse effects
Supralingual
active group
Sublingual
active group
Supralingual
placebo groups
Sublingual
placebo groups
Cases Patients Cases Patients Cases Patients Cases Patients
Local adverse effects
Undesirable taste 0 0 0 0 2 1 0 0
Difficult swallowing 2 1 0 0 0 0 0 0
Tongue swelling 1 1 3 1 0 0 0 0
Plicae sublinguales swelling 0 0 3 1 0 0 0 0
Lips swelling 2 1 0 0 0 0 0 0
Lips burning 3 1 0 0 0 0 0 0
Mouth burning 0 0 0 0 1 1 0 0
Tongue burning 0 0 1 1 0 0 0 0
Throat burning 1 1 0 0 0 0 0 0
tongue itching 5 2 0 0 0 0 0 0
Throat itching 2 2 0 0 0 0 0 0
Mouth itching 6 3 4 2 1 1 1 1
Total local AE 22 5 11 3 4 3 1 1
Systemic adverse effects
Rhinitis 7 3 19 4 0 0 0 0
Painful breathing 1 1 0 0 0 0 0 0
Difficult breathing 0 0 4 2 0 0 0 0
Breathlessness 0 0 1 1 0 0 0 0
Cough 1 1 1 1 0 0 0 0
Conjunctivitis 10 4 7 3 0 0 0 0
Sneezing 1 1 0 0 0 0 0 0
Ear itching 5 1 0 0 0 0 0 0
Abdominal pain 0 0 0 0 1 1 0 0
Headache 4 2 1 1 0 0 0 0
Heartburn 1 1 0 0 0 0 0 0
Nausea 3 1 0 0 0 0 0 0
Fatigue 0 0 1 1 0 0 0 0
Total systemic AE 33 9 34 6 1 1 0 0
Evaluation of grass pollen specific immunotherapy 1303of the product and they were expected. Only one special
local effect, swelling of sublingual ridges (plicae sublin-
guales) was observed in one patient of the sublingually
treated group. In three of the patients of the sublingual
group, respiratory difficulties were represented by morn-
ing breathlessness and difficult or painful breathing.
Because of the short and temporary duration of these dif-
ficulties, allergen immunotherapy was not discontinued.
The adverse events that occurred in the trial are pre-
sented in Table 5.
In active groups, 0.32% of local and 1.00% of systemic
adverse effects were registered from a number of 3392
sublingually administered doses and 0.57% of local and
0.86% systemic adverse effects of 3856 supralingually
administered doses.Discussion
This multicentric study compared a six grass pollen allergen
extract administered sublingually or supralingually as oral
drops with placebo. The number of patients evaluated was
sufficiently large and the study population was welldefined, with the baseline characteristics of both treat-
ment groups and placebo groups being similar both at the
onset and upon completion of the study.
The results of this trial support the evidence that
a slow absorption and processing of the locally retained
allergen occurs through the local oral immune system.2 In
addition, the allergen absorption seems to be consider-
ably higher for allergens placed under the tongue (sublin-
gual administration) rather than on the tongue
(supralingual administration).
Clinical improvement assessed by means of symptom
scores and rescue medication consumption supports the
statement mentioned above because the results were
highly significant in the sublingually treated patients vs.
the placebo group, whereas in supralingually treated
patients, there was a significant difference only in the
nasal symptom score compared to placebo-treated pa-
tients. Moreover, the symptom scores and drug consump-
tion were almost twice as high in patients with
supralingually administered oral drops as in patients of
the sublingual active group.
Also the percentage of increase of Dactylis glomerata
specific IgG levels achieved in sublingually treated patients
1304 P. Panzner et al.(138.8%) in comparison to the supralingual active (74.1%)
and placebo groups (63.1% and 7.9%) corresponds to this
reasoning.
Moreover, symptom scores and drug intake, especially
during the peak of the grass pollen season, showed a signif-
icant difference with reduction of over 60% in patients
treated with the sublingual active therapy. It can be
supposed that the unambiguous significance was achieved
due to the high cumulative dose5,8,10 and rule of scoring
in diary: Patients received allergen doses (cumulative
dose of about 600 000 JSK in one year of immunotherapy)
almost 20 times higher than those generally administered
by the parenteral route using the corresponding allergenic
preparation. Rule of symptom scoring requires at least
one symptom with 3 points score to allow use of rescue
medication. These results are not inconsistent with the
results reported elsewhere in the literature.3e7,11,12,15
The significant Dactylis glomerata specific IgG level
increase observed in this study and in the literature7,12
provides evidence that sublingual immunotherapy has an
effect on the immune system. Because of the influence of
two factors, the effect of specific immunotherapy and the
exposure to grass pollen,5 the increase in specific IgE was
greater in both placebo groups than in both active groups
whereas the increase of specific IgG was greater in the
sublingual active group than in the supralingual and placebo
groups. These data should be interpreted with respect to
the mild grass pollen season (daily mean of pollen count
was 16.9 grain/m3).
Most of the adverse events were mild local reactions
concerning the oral cavity that did not require special
treatment. All the active treated patients showed a
very good tolerance of the immunotherapy, and the safety
of the sublingual and supralingual routes was also associ-
ated with good clinical efficacy in favor of sublingual
treatment.
In conclusion, this trial demonstrated that both of these
routes of administration are safe and provide clinical
benefits including significant improvements in rhinitis,
conjunctivitis and eventually bronchial symptoms on reduc-
tion of drug intake in favor of sublingual immunotherapy.Conflicts of interest
The authors have no conflict of interest.Acknowledgments
We thank the following physicians participating in the study
as investigators: M. Kacı´rkova´, M. Kasl, J. Kr´ikavova´, J.
Kotasova´, L. Pennigerova´, V. Sˇtruplova´, L. Tamele, I.
Vondra´kova´. Special thanks must also be given to C. Andry´s,
Department of Clinical Immunology and Allergology, Faculty
of Medicine, Hradec Kra´love´, Charles University in Prague.
The work was supported by grant VZ MSM 0021620812.References
1. Bousquet J, Lockey RF, Malling H-J. WHO position paper.
Allergen immunotherapy: therapeutic vaccines for allergic
diseases. Allergy 1998;53(Suppl.):1e42.
2. Fanta C, Bohle B, Hirt W, Siemann U, Horak F, Kraft D, et al.
Systemic immunological changes induced by administration of
grass pollen allergens via the oral mucosa during sublingual
immunotherapy. Int Arch Allergy Immunol 1999;120:218e24.
3. Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P,
Parmiani S, et al. Clinical and immunologic effects of a rush sub-
lingual immunotherapy toParietaria species: a double-blind, pla-
cebo-controlled trial. J Allergy Clin Immunol 1999;104:964e8.
4. Purello-D’AmbrosioF,Gangemi S, Isola S,LaMottaN,Puccinelli P,
Parmiani S,etal. Sublingual immunotherapy: adouble-blind,pla-
cebo-controlled trial with Parietaria judaica extract standard-
ized in mass units in patients with rhinoconjunctivitis, asthma,
or both. Allergy 1999;54:968e73.
5. Pradalier A, Basset D, Claudel A, Couturier P,Wessel F, Galvain S,
et al. Sublingual-swallow immunotherapy (SLIT)witha standard-
ized five-grassepollen extract (drops and sublingual tablets)
versus placebo in seasonal rhinitis. Allergy 1999;54:819e28.
6. Di Rienzo V, Puccinelli P, Frati F, Parmiani S. Grass pollen
specific sublingual/swallow immunotherapy in children: open-
controlled comparison among different treatment protocols.
Allergol Immunopathol (Madr) 1999;27:145e51.
7. Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunother-
apy with a standardised grass pollen extract; a double-blind
placebo-controlled study. Allergol Immunopathol (Madr)
1998;26:234e40.
8. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C,
et al. Double-blind, placebo-controlled evaluation of sublingual
immunotherapywith standardizedolivepollenextract inpediat-
ric patients with allergic rhinoconjunctivitis and mild asthma
due to olive pollen sensitization. Allergy 1998;53:662e72.
9. Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-
swallow immunotherapy: a double-blind, placebo-controlled
trial of a standardized five-grass-pollen extract in rhinitis.
Allergy 1998;53:493e8.
10. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual
versus injective immunotherapy in grass pollen allergic
patients: a double blind (double dummy) study. Clin Exp
Allergy 1996;26:1253e61.
11. Purello-D’ambrosio FP, Ricciardi L, Isola S, Puccinelli P,
Musarra A. Rush sublingual immunotherapy in Parietaria aller-
gic patients. Allergol Immunopathol (Madr) 1996;21:146e51.
12. Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double-
blind, placebo-controlled trial by the sublingual route of
immunotherapy with a standardized grass pollen extract.
Allergy 1994;49:309e13.
13. Wilson DR, Torres Lima M, Durham SR. Sublingual immunother-
apy for allergic rhinitis: systematic review and meta-analysis.
Allergy 2005;60:4e12.
14. Malling Hans-Jorgen. Comparison of the clinical efficacy and
safety of subcutaneous and sublingual immunotherapy:
methodological approaches and experimental results. Curr
Opin Allergy Clin Immunol 2004;4:539e42.
15. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized
controlled trial of high-dose sublingual immunotherapy to treat
seasonalallergic rhinitis.JAllergyClin Immunol2004;114:831e7.
16. D’Amato G, Spieksma FthM, Liccardi G, Ja¨ger S, Russo M,
Kontou-Fili K, et al. Position paper. Pollen-related allergy in
Europe. Allergy 1998;53:567e85.
